Richard L. Dunbar

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Preventive Cardiovascular Medicine Clinic, University of Pennsylvania School of Medicine
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Member, Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine
Department: Medicine

Contact information
Perelman School of Medicine at the University of Pennsylvania
3600 Spruce Street
8-046 Maloney Building
Philadelphia, PA 19104-2699
Office: Clinic (215) 615-8659
Lab: (215) 315-3378
Education:
B.A. (Environmental Sciences)
University of Virginia, Charlottesville, VA, 1992.
M.D. (Medicine)
Medical College of Virginia, Richmond, VA, 1997.
M.S. (Translational Research)
University of Pennsylvania School of Medicine, Philadelphia, PA, 2008.
Permanent link
 

Description of Research Expertise

Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of nicotinic acid (niacin). He has developed sophisticated objective techniques to quantify the physical stigmata of flushing from niacin. He combines these techniques with laboratory pharmacodynamic studies to elucidate the integrated physiology of the response to niacin.

Description of Itmat Expertise

Dr. Dunbar studies the dyslipidemia of metabolic syndrome and type 2 diabetes and is involved in mechanistic clinical research related to high-density lipoprotein, triglycerides, and post-prandial lipidemia. He has a particular interest in understanding the mechanism of action and mechanism of adverse effects of niacin. Dr. Dunbar can accommodate a limited number of research observerships.

Selected Publications

Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ: Effects of Niacin, Statin, and Fenofibrate on Circulating PCSK9 Levels in Patients with Dyslipidemia. American Journal of Cardiology October 2014 Notes: Accepted 10/17/2014 and published online; print version expected in 1/2015.

Song W, Stubbe J, Ricciotti E, Dunbar RL, Rader DJ, FitzGerald GA: Systemic Eicosanoid and Cytokine Response to Niacin: Implications in HPS2-THRIVE Trial and Beyond [Poster Presentation] Journal of Clinical Lipidology 8(3): 309, June 2014 Notes: National Lipid Association 2014 Annual Scientific Sessions, May 1-4, 2014, Orlando, FL.

Donovan J, Dunbar R, Biernat L, Logan D, Curtis M, Mancini M, Jirousek M: Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Demonstrates Reductions in Postprandial Triglycerides [Poster Presentation] Journal of Clinical Lipidology 8(3): 311, June 2014 Notes: National Lipid Association 2014 Annual Scientific Sessions, May 1-4, 2014, Orlando, FL.

Tuteja S, Duffy D, Dunbar RL, Movva R, Gadi R, Bloedon LT, Cuchel M : Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia. Pharmacotherapy 34(3): 213–314, March 2014.

Donovan J, Dunbar R, Biernat L, Logan D, Curtis M, Mancini M, Jirousek M: Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Demonstrates Reductions in Postprandial Triglycerides [Poster Presentation] JACC March 2014 Notes: 63rd Annual Scientific Session of the American College of Cardiology, Washington, DC, March 2014.

Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH: A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). Clinical Therapeutics 35(9): 1400-1411, September 2013.

Maki KC, Orloff D, Niholls S, Dunbar R, Roth E, Johnson J, Kling D, Davidson MH: Epanova Lowers Apolipoprotein C-III and Increases LDL-Particle Size in Statin-Treated Patients With Mild Hypertriglyceridemia [Poster Presentation] Journal of Clinical Lipidology 7(3): 269, May 2013 Notes: National Lipid Association 2013 Annual Scientific Sessions, May 31-June 2, 2013, Las Vegas, NV.

Dunbar RL, Cuchel M, Millar JS, Baer A, Poria R, Freifelder RH, Pryma DA, Billheimer JJ, Rader DJ: Niacin Does Not Accelerate Reverse Cholesterol Transport in Man [Poster Presentation] ATVB April 2013 Notes: Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, Lake Buena Vista, FL, April 2013.

Tuteja S, Dunbar R, Qu L, Li M, Mucksavage M, DerOhannessian S, Reilly M, Rader DJ: Perilipin 1 (PLIN1) genotype and not GPR109A associated with free fatty acid rebound following niacin administration [Poster Presentation] ATVB April 2013 Notes: Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, Lake Buena Vista, FL, April 2013.

deGoma,EM* and Dunbar, RL*, Jacoby, D, and French, B: Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations. Atherosclerosis 227(1): 172-7, March 2013 Notes: *Co-first authors, equal contribution.

back to top
Last updated: 12/17/2014
The Trustees of the University of Pennsylvania